论文部分内容阅读
前言所有抗结核治疗方案都可以引起副作用,但这些副作用必须与活动性结核得不到合理治疗的危险权衡得失。目前我以INH加上一或二种其他药物,疗程十二个月或更长的标准方案,与近代的治疗方案(即有利福平(RFP)或吡嗪酰胺(PZA)或两者都有的方案),加以讨论,重点讨论肝炎及特别有临床重要性的其他副作用。应用INH加上一种或多种药物中的肝炎我们可以正确地测定疗程一年或更长的标准化疗的肝炎发生率,因为对标准疗法进行过多次对照研究工作及严密的观察,肝炎不可能被遗漏。许多国家的这类研究中,肝炎发生的频率(见表一)两个国际协作的研究包括欧、亚、非二十个国家,肝炎发生频率约为1～2％。在73名肝炎病人中有9人死亡(其中8人用INH+TB1,1人用INH+
Foreword All anti-tuberculosis treatment programs can cause side effects, but these side effects must be weighed against the dangers of lack of proper treatment of active tuberculosis. Currently I am using INH plus one or two other medications, a standard regimen of twelve months or longer, and a modern regimen (ie, RFP or PZA) or both ), To be discussed, focusing on hepatitis and other side effects of particular clinical importance. Apply INH plus hepatitis in one or more drugs We can correctly measure the incidence of hepatitis with standard chemotherapy for one year or more because of multiple controlled studies and close observation of standard therapies, May be missing. The incidence of hepatitis in these studies in many countries (see Table 1) shows that two international collaborative studies include about 20% of hepatitis in 20 countries in Europe, Asia and Africa. Nine out of 73 hepatitis patients died (8 of them with INH + TB1, 1 for INH +